BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36598065)

  • 21. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
    Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
    Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications for pro-GRP in small cell lung cancer. A single center experience.
    Cavalieri S; Morelli D; Martinetti A; Galli G; Nichetti F; de Braud F; Platania M
    Int J Biol Markers; 2018 Jan; 33(1):55-61. PubMed ID: 28967066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR; Zhang X; Xu ZF; Zheng S
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
    Li L; Zhang Q; Wang Y; Xu C
    J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis.
    Giovanella L; Piantanida R; Ceriani L; Bandera M; Novario R; Bianchi L; Roncari G
    Int J Biol Markers; 1997; 12(1):22-6. PubMed ID: 9176714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer.
    Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J
    J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing Diagnostic Accuracy for Lung Cancer through Combined Detection of Multiple Tumor Markers.
    Qing G; Jiang X; Xu G; Liu T; Deng T
    Altern Ther Health Med; 2023 Nov; 29(8):36-41. PubMed ID: 37632966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
    Yang J; Jiao S; Kang J; Li R; Zhang G
    Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy].
    Ohnoshi T; Ueoka H; Segawa Y; Kiura K; Tabata M; Shibayama T; Maeda T; Miyatake K; Takigawa N; Kimura I
    Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Feb; 30(2):262-9. PubMed ID: 1351108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
    Lu QQ; Li J; Li YH; Liu H; Xie XB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.
    Park J; Yang JS; Jung G; Woo HI; Park HD; Kim JW; Huh W; Ko JW; Kim H; Cho JY; Lee SY
    J Proteomics; 2013 Dec; 94():302-10. PubMed ID: 24120528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
    Plebani M; Basso D; Navaglia F; De Paoli M; Tommasini A; Cipriani A
    Br J Cancer; 1995 Jul; 72(1):170-3. PubMed ID: 7541234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
    Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.